Covagen's Series B Round

Covagen raised a round of funding on December 09, 2013.

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflamma…

Articles about Covagen's Series B Round: